Advances by Anvisa in 2026 reinforce debate on research and public policies in the sector

The Federal University of Rio Grande do Norte (UFRN) has become the first institution in Brazil authorized by Anvisa to carry out controlled cultivation and processing of cannabis for scientific research. The planting takes place in an indoor system at the Brain Institute (ICe-UFRN), focusing on studies on epilepsy, autism, pain, sleep, and other neurological disorders

Anvisa warns of risk of pancreatitis and reinforces that slimming pens require prescription and medical monitoring.

In an interview with the CB.Poder program of Correio Brasiliense, conducted by journalists Adriana Bernardes and Sibele Negromonte, Leandro Safatle, acting CEO of Anvisa, detailed the behind-the-scenes and expectations regarding the new regulation of medicinal cannabis and research in Brazil

Director of Institutional Relations evaluates national cultivation, new RDCs from Anvisa, and the challenges to consolidate the sector in the country

Imported product with medical prescription and authorization from Anvisa is being held by Federal Revenue at Gollog cargo terminal in Guarulhos

Correction published in the Official Gazette clarifies requirements on packaging and maintains authorization for magistral manipulation of CBD

Resolution No. 1,015/2026 tightens technical requirements, expands sanitary controls, and consolidates authorization as a transitional step before the registration of medicines

New RDC No. 1,011 expands regulatory details on Cannabis derivatives, medicinal products, and pharmaceutical inputs

Anvisa proposes exclusive process for the regulation and experts point out impact on the sector

Despite technical feasibility, Anvisa conditions the production of cannabidiol on the publication of a specific regulation, with validity in 90 days

The topic was discussed during a lecture at the 43rd CIOSP, the largest dentistry congress in Latin America, focusing on scientific evidence and the impacts of Anvisa's new regulations on dental practice in the treatment of orofacial pain.

Agency defines a modular strategy for cannabis cultivation, establishing distinct rules for patient associations, research, and industry

Revision of RDC 327 allows the compounding sector to produce derivatives, while individual importation by individuals remains under old rules and will be analyzed separately

Anvisa's proposal establishes a new regulatory framework for industrialized medicinal cannabis products in Brazil

Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow

Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow

Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate

New resolution allows planting by universities and pharmaceutical industries, requiring maximum security systems and total traceability of the plant

Proposal aims to regulate the performance of non-profit entities in a controlled experimental environment, using the Regulatory Sandbox model to comply with STJ decision